Sanofi Pasteur announced that the Food and Drug Administration (FDA) has approved the use of Menactra (meningococal [Groups A, C, Y, W-135] polysaccharide diphtheria toxoid conjugate vaccine) for booster vaccination against meningococcal disease in patients aged 15–55 years.

The new approval for Menactra was based on results of an open-label trial that studied the safety and immunogenicity of a booster dose among patient who received Menactra 4–6 years earlier.

RELATED: 2014 Vaccination Schedule: Adults

Menactra was approved in January 2005 as the fist quadrivalent conjugate vaccine in the United States for active immunization against meningococcal disease caused by the serogroups A, C, Y, W-135. It is currently approved for vaccination in patients 9 months–55 years old.

For more information visit SanofiPasteur.US.